Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 (Certican) in pediatric de novo renal transplant recipients
2005-002372-16Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in Kidney allograft status (RTx), sponsored by Novartis. Primary endpoints: Primary safety and tolerability and Efficacy: acute rejection, graft loss, or death at 6 and 12 months. Started Sep 2005; status: completed.
02
Drugs
everolimus
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2005-002372-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002372-16.